Reata Pharmaceuticals, Inc.

In what observers are calling a sensible deal for both sides, Stoke Therapeutics and Biogen revealed on 18 February that they will collaborate on development and commercialization of Stoke’s antisense

CEO Christopher Viehbacher has been straightforward about Biogen’s challenges since taking the helm in November 2022, and that did not change as the company reported its fourth-quarter and full-year 2

Another day and another deal in the molecular glue degrader (MGD) space has been inked, with Biogen the latest major company keen to explore the potential of protein degradation for previously undrugg

A team at Atlas Venture began working on how to deliver small interfering RNA (siRNA) to the kidney three years ago and created a platform similar to technologies that have emerged for delivering olig